⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109855 | 0.75 | — | — | |
| SCHEMBL29391076 | 0.75 | — | — | |
| SCHEMBL30151389 | 0.75 | — | — | |
| SCHEMBL858342 | 0.75 | — | — | |
| SCHEMBL1586143 | 0.75 | — | — | |
| SCHEMBL31656490 | 0.75 | — | — | |
| SCHEMBL30901327 | 0.75 | — | — | |
| SCHEMBL56192 | 0.75 | — | — | |
| SCHEMBL879562 | 0.75 | — | — | |
| SCHEMBL1428398 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108689949-A | A kind of pyridine derivatives and preparation method thereof | 湖南华腾制药有限公司 | 2018-10-23 | — | — | CN | claimed |
| EP-4727652-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| CN-121270482-A | Preparation method of 4-amino-2-chloro-5-methylpyrimidine | 山东中新科农生物科技有限公司 | 2026-01-06 | — | — | CN | disclosed |
| CN-121270482-A | Preparation method of 4-amino-2-chloro-5-methylpyrimidine | 山东中新科农生物科技有限公司 | 2026-01-06 | — | — | CN | disclosed |
| EP-4658662-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12391676-B2 | BRD4-JAK2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | disclosed |
| CN-120058737-A | Cyclic compounds as JAK2 inhibitors and uses thereof | 华东师范大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1549316-A1 | INHIBITORS OF TFG&bgr; | SCIOS INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004074278-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | disclosed |
| US-20040132730-A1 | Inhibitors of TGFbeta | SCIOS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |